Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Health Care M&A Deals, Week Ending April 12, 2019
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online can help you stay up-to-date on the healthcare market overall, or in a particular sector of interest to your firm. Behavioral Health Care Acquirer Target Price Principal Real Estate Spezialfondsgesellschaft mbH Privatklinik Friedenweiler clinic N/A Sprout Health Group Endeavor House North N/A Biotechnology Acquirer Target Price Ocugen, Inc. Histogenics Corporation N/A XOMA Corporation Rights to... Read More »
Healthcare Deal Spending Was Healthy in March 2019
March 2019’s combined spending, at nearly $25 billion, is a healthy-looking sum, even though it represents a 24% drop compared with February 2019 and a 65% decline versus March 2018. As usual, March 2019’s total is mostly the result of one deal—Centene’s (NYSE: CNC) $17.4 billion bid for WellCare Health Plans (NYSE: WCG), which accounted for 70% of the total. Without it, March 2019 would have posted a total of $7.5 billion and a 77% decrease from the previous month’s approximately $32.8 billion. And an almost 90% drop compared with the $71.5 billion in March 2018. Spending isn’t the real measure of the health of the healthcare deal market, as we say every month. Sources tell us they see... Read More »
March Healthcare Deal Volume Dribbled Off
It was a slow first quarter, and March’s monthly deal results didn’t change that fact. Just 115 transactions were announced, following February’s total of 106. Compared with March 2018’s 149 deals, last month’s deal volume sank 23%. The over-heated market we saw in 2018 is cooling, at least momentarily. Of course, there was a time when seeing 115 deals in a month was unusual. Dare we say, exciting? But that was so five years ago, to be exact. In March 2014, there were 97 transactions made public, up just a sliver from the 95 announced in February 2014. With the exception of August 2014 (another slow month with 95 deals), monthly deal volume has stayed above the 100-mark ever since.... Read More »
Q1:2019 Healthcare Deal Volume Slowed
Talk of slowing global economic growth has swirled since late last year, following tariffs, trade wars, Brexit and you-name-it. The healthcare M&A market appeared to reflect the fears, as deal volume in the first quarter of 2019 slid 27% compared with the fourth quarter of 2018, and was down 19% compared with the same quarter a year ago. Granted, matching the nearly 500 deals reported in the record-making fourth quarter would be a stretch even in better times. But with preliminary data showing just 362 transactions recorded in the first quarter, we’re certainly looking at a slowdown in healthcare deals. Last year in the same period, 447 deals were announced. We’ve talked with a lot of... Read More »
Healthcare M&A Spending Spiked in Q1:2019
Spending in the first quarter, totaling $149 billion, beat both the previous quarter (up 239%) and the year-ago time period (up 31%). Three deals had a combined total of $113 billion, accounting for 76% of that spending. Without those three, the first quarter would have ended with approximately $36 billion, which would be 18% lower than the fourth quarter of 2018 ($44 billion) and 68% lower than the first quarter in 2018 ($113 billion). Those big deals began coming early on, beginning with the $74 billion acquisition of biotech biggie Celgene Corp. (NASDAQ: CELG) by Bristol-Myers Squibb (NYSE: BMY) on January 3. The deal put Bristol-Myers deeper into the highly competitive and highly... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
